Progenitor Cell Therapy Announces Collaboration with BD to Co-Develop and Market Assays for the Growing Cell Therapy Industry
Progenitor Cell Therapy, LLC (PCT), a leading cell therapy manufacturing and services company, today announced an agreement with BD Biosciences, a segment of Becton, Dickinson and Company (BD), to co-develop and market products and services for the cell therapy industry, including: product characterization and comparability assays; in-process and final product release tests; and PCT’s contract cell therapy development and manufacturing platform resources.
Article
GE Healthcare and Saneron Announce a Research Collaboration for the Development of Umbilical Cord Blood Processing
GE Healthcare, a unit of General Electric Company (NYSE: GE), and Saneron today announced an R&D agreement to optimize GE Healthcare’s Ficoll-Paque™ for the isolation of stem cells from umbilical cord blood.
Article
Stem Cell Sciences Advances Towards Its First Cell Therapy Program for Degenerative Disease
Stem Cell Sciences plc (AIM: STEM), the global stem cell company, today announced that Stem Cell Sciences KK (SCS KK), an affiliated company of Stem Cell Sciences plc (SCS plc) in Japan, has signed a worldwide exclusive license agreement with The Universite de Nice Sophia-Antipolis, France (University of Nice), to commercialise human multipotent adipose-derived stem cells (hMADS) and technologies which will form the basis for a cell therapy programme focused on degenerative diseases including Duchenne Muscular Dystrophy (DMD).
Article
FDA Clears Baxter’s Amicus for Seven-day Storage of Platelets
The FDA has granted 510(k) clearance for the seven-day storage of a type of blood platelets collected on Baxter Healthcare’s Amicus Separator and stored in Baxter’s PL 2410 collection container.
Article
Osteotech Grafton(R) DBM Family of Products Receives FDA 510(k) Clearance Extension
Osteotech, Inc. (Nasdaq: OSTE) announced today that it has been informed by the Food and Drug Administration (“FDA”) that FDA is granting Osteotech an extension to clear its previously filed Grafton(R) DBM 510(k) applications until such time as the Agency is able to complete its work on the applications.
Article
First Oncolytic Viral Therapy Approved for Head and Neck Cancer
Shanghai Sunway Biotech Co. Ltd. announced today that the Chinese State Food and Drug Administration (SFDA) has approved H101, an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory Nasopharyngeal cancer, a type of head and neck cancer prevalent in China.
Article
Norwood Immunology – Phase II Clinical Trial – Melanoma Cancer Vaccine; First Patient Injected
Norwood Abbey Limited (OTC:NABYF) (ASX:NAL) today announced that its subsidiary, Norwood Immunology Limited (AIM:NIM), a company focussed on the rejuvenation of the immune system, commenced its Phase II clinical trial.
Article
Vaccine Administered Following Pancreatic Cancer Surgery and Adjuvant Therapy
Cell Genesys, Inc. (Nasdaq: CEGE) today announced interim findings from a Phase 2 clinical trial of GVAX(R) vaccine for pancreatic cancer in 60 patients with operable pancreatic cancer who received the vaccine after surgical resection of their tumor and adjuvant radiation and chemotherapy.
Article
ReNeuron announces First Results from Key Pre-clinical Safety Studies with its Lead ReN001 Stem Cell Line for Stroke
ReNeuron Group plc (LSE: RENE.L) today announced that it has generated provisional pre-clinical data indicating that its lead ReN001 cell line for stroke does not form tumours following implantation.
Article
Neurologix Pre-Clinical Results Show Potential for Gene Therapy Treatment of Huntington’s Disease
Neurologix, Inc. (OTCBB: NRGX) today announced findings from preclinical studies, which showed that the gene XIAP (X-linked inhibitor of apoptosis) may prevent the progression of Huntington’s disease.
Article
ReGen Biologics, Inc. Signs Exclusive Distribution Agreement For Spain
ReGen Biologics, Inc. (OTC:RGBI) an orthopedic products company that develops, manufactures, and markets innovative tissue growth and repair products, announced today an exclusive two-year distribution agreement with Hoscenter to market the ReGen(R) CMI(TM) in most areas of Spain.
Article
Mozobil(TM) Abstracts Accepted for Presentation at the American Society of Hematology Conference
AnorMED Inc. (AMEX:AOM;TSX:AOM) announced today that 12 clinical and preclinical abstracts on MOZOBIL(AMD3100), a first in class stem cell mobilizer, have been accepted for presentation at the American Society of Hematology (ASH) annual meeting, being held in Atlanta, Georgia, December 10-13th, 2005.
Article
ImmunoGen, Inc. Announces Presentation of HuN901-DM1 Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
As reported today, clinical activity seen with huN901-DM1 in this study includes a complete remission lasting at least 15 weeks and stable disease lasting up to 18 weeks.
Article
Inex to Spin Off Targeted Immunotherapy Assets into New Company
Shares of Inex Pharmaceuticals Corp. gained more than 20 per cent Thursday after the drug developer said it plans to spin off part of its business into a new company and focus on the development of its anti-cancer treatment Marqibo.
Article
Ellen Areman Joins BCG
Ellen Areman, MS, SBB (ASCP) has joined the Biologics Consulting Group, LLC, as a Senior Consultant
Article